Suppr超能文献

癌基因蛋白共表达。Ha-ras、c-myc、c-fos和p53作为乳腺癌预后判别指标的价值。

Oncogene protein co-expression. Value of Ha-ras, c-myc, c-fos, and p53 as prognostic discriminants for breast carcinoma.

作者信息

Bland K I, Konstadoulakis M M, Vezeridis M P, Wanebo H J

机构信息

Department of Surgery, Brown University School of Medicine, Providence, Rhode Island, USA.

出版信息

Ann Surg. 1995 Jun;221(6):706-18; discussion 718-20. doi: 10.1097/00000658-199506000-00010.

Abstract

OBJECTIVE

A refinement of prognostic variables using traditional pathologic markers integrated with oncogene proteins, enzymes, and hormonal factors may enhance the ability to predict for recurrence or survival in patients with mammary carcinoma. Although various oncogenes and oncogene products have been identified in human breast carcinoma, their relationship to disease outcome remains controversial.

METHODS

Using the monoclonal antibodies cS93.1, 9E1.0, F235-1.7.1, and PAb 1801 against each oncogene protein studied, the avidin-biotin complex immunoperoxidase method provided immunohistochemical staining of bound oncogene protein for c-fos, c-myc, Ha-ras, and p53, respectively. Analyses were made on archival pathology tissues of 85 breast cancer patients (stages I, IIA, and IIB). Forty patients (47%) had recurrence of disease; 45 remained free of local-regional or distant disease at mean follow-up of 48 months (range 6-180 months). Molecular biological data were merged with clinicopathologic demographics 1) to determine the frequency of single or co-expression of oncogenes in this patient population; 2) to evaluate the value of these molecular protein markers to predict probability of recurrence; and 3) to determine worth of the studied oncogenes to correlate with traditional clinical pathologic parameters and overall survival.

RESULTS

In this study, oncogene expression had statistical correlation for recurrence with increasing co-expression: one oncogene 17.2%, two oncogenes 56.3%, three or four oncogenes, 100% (p = 0.001). Increasing oncogene or co-oncogene expression correlated with statistically significant reduction in disease-free and overall survival; with no expression of oncogenes, disease-free survival was 30 (SE +/- 5.7) months and overall survival was 56.4 (SE +/- 4.57) months. With expression of three oncogenes, disease-free survival was 12 (SE +/- 1.23) months (p = 0.0018) and overall survival was 23.4 (SE +/- 3.38) months (p = 0.0025). In univariate Wilcoxon analysis, oncogene expression was the most significant variable to determine survival (p = 0.035); in multivariate analysis, age and oncogene co-expression each emerged as the most significant variables for overall survival. For the proportional hazards regression model, oncogene co-expression was significant (p = 0.0104, risk-ratio 1.914) and correlated with age and tumor size as significant variables. Ha-ras and c-fos both emerged as important individual oncogene proteins to affect survival (p = 0.0925, risk-ratio 3.517 and p = 0.025, risk-ratio 4.214, respectively). The proto-oncogene c-myc and the antitumor suppressor gene p53 did not have significant effects as individual oncogenes to influence survival.

CONCLUSIONS

Approximately one fifth of the breast cancer patients in this analysis (disease-free and recurrent) expressed only a single oncogene marker (c-fos, c-myc, Ha-ras, or p53); one quarter of patients with recurrent disease expressed only one oncogene protein. Single oncogene expression did not possess independent prognostic significance for prediction of recurrence. Further, p53 mutations did not function as independent correlates for prognosis. The co-expression of the studied proto-oncogenes (c-myc, Ha-ras) and the nuclear transcriptional protein (c-fos) functioned as a strong prognostic correlate for recurrence and survival; the effect of individual oncogenes to predict survival was greatest for Ha-ras and c-fos. Immediate or early co-expression of three oncogene proteins in neoplastic transformation endowed cells of invasive carcinoma with an aggressive phenotype. This aggressive phenotype was evident in a small percentage of the studied population (11%) and predicted adverse disease-free and overall survival. These findings suggest that oncogene co-expression possesses significant prognostic and potential therapeutic value; incorporation of this molecular technology into future prospective randomized trials is advisable.

摘要

目的

将传统病理标志物与癌基因蛋白、酶及激素因子相结合,对预后变量进行优化,可能会提高预测乳腺癌患者复发或生存的能力。尽管在人类乳腺癌中已鉴定出多种癌基因和癌基因产物,但其与疾病转归的关系仍存在争议。

方法

使用针对所研究的每种癌基因蛋白的单克隆抗体cS93.1、9E1.0、F235-1.7.1和PAb 1801,抗生物素蛋白-生物素复合物免疫过氧化物酶法分别对结合的癌基因蛋白c-fos、c-myc、Ha-ras和p53进行免疫组织化学染色。对85例乳腺癌患者(I期、IIA期和IIB期)的存档病理组织进行分析。40例患者(47%)疾病复发;45例在平均48个月(范围6 - 180个月)的随访中无局部区域或远处疾病。将分子生物学数据与临床病理人口统计学数据合并:1)确定该患者群体中癌基因单一或共表达的频率;2)评估这些分子蛋白标志物预测复发概率的价值;3)确定所研究的癌基因与传统临床病理参数及总生存相关的价值。

结果

在本研究中,癌基因表达与复发的相关性随共表达增加而具有统计学意义:一种癌基因17.2%,两种癌基因56.3%,三种或四种癌基因100%(p = 0.001)。癌基因或共癌基因表达增加与无病生存期和总生存期的统计学显著降低相关;无癌基因表达时,无病生存期为30(标准误±5.7)个月,总生存期为56.4(标准误±4.57)个月。有三种癌基因表达时,无病生存期为12(标准误±1.23)个月(p = 0.0018),总生存期为23.4(标准误±3.38)个月(p = 0.0025)。在单变量Wilcoxon分析中,癌基因表达是确定生存的最显著变量(p = 0.035);在多变量分析中,年龄和癌基因共表达均成为总生存的最显著变量。对于比例风险回归模型,癌基因共表达具有显著性(p = 0.0104,风险比1.914),并与年龄和肿瘤大小作为显著变量相关。Ha-ras和c-fos均成为影响生存的重要单个癌基因蛋白(分别为p = 0.0925,风险比3.517和p = 0.025,风险比4.214)。原癌基因c-myc和抗肿瘤抑制基因p53作为单个癌基因对生存无显著影响。

结论

在本分析中,约五分之一的乳腺癌患者(无病和复发患者)仅表达一种癌基因标志物(c-fos、c-myc、Ha-ras或p53);四分之一的复发患者仅表达一种癌基因蛋白。单癌基因表达对预测复发不具有独立的预后意义。此外,p53突变不作为预后的独立相关因素。所研究的原癌基因(c-myc、Ha-ras)和核转录蛋白(c-fos)的共表达是复发和生存的强预后相关因素;单个癌基因对生存的预测作用在Ha-ras和c-fos中最为显著。在肿瘤转化过程中三种癌基因蛋白的即时或早期共表达赋予浸润性癌细胞侵袭性表型。这种侵袭性表型在一小部分研究人群(11%)中明显,并预测不良的无病生存期和总生存期。这些发现表明癌基因共表达具有显著的预后和潜在治疗价值;建议将该分子技术纳入未来的前瞻性随机试验。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e710/1234700/9e092705e5b3/annsurg00052-0110-a.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验